Sunday, October 19, 2025 from 4:00 p.m. to 5:30 p.m. CDT at Lakeshore, 1st Floor
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-25-140-L01-PActivity Type: A Knowledge-Based ActivityThis presentation will delve into the complexities of cellular therapy toxicities and the latest product and indication updates in the realm of solid tumors. Attendees will gain insights into the diverse toxicity profiles associated with various cellular therapies, including both common and rare adverse events. The session will highlight recent advancements in treatment protocols and emerging therapies, emphasizing their implications for patient management and care. By examining real-world data and clinical experiences, the presentation aims to equip healthcare professionals with practical strategies for toxicity mitigation and improved patient outcomes, fostering a deeper understanding of how to navigate the evolving landscape of hematology-oncology therapies.
Learning Objectives1. Outline the paradigm shift in the treatment of patients with solid tumors toward cellular therapy.
2. Discuss key literature leading to the approval of novel, cellular therapies for the treatment of solid tumors.
3. Review toxicity profiles of cellular therapies used in solid tumor versus hematologic malignancies.
4. Explore strategies to mitigate toxicities associated with cellular therapies.
5. Review monitoring and treatment plan for a patient with a solid tumor receiving a novel cellular therapy.
Paradigm Shift: The Movement Toward Cellular Therapy for the Treatment of Solid Tumors4:00 p.m. to 4:45 p.m. | | Speaker: | Farah Raheem, Pharm.D., BCOP | | Clinical Oncology Pharmacist
Mayo Clinic, Phoenix, AZ | | View Biography |
|
|
Toxicity Management: Strategies to Mitigate and Treat Cellular Therapy-Related Adverse Events4:45 p.m. to 5:30 p.m. | | Speaker: | Jessica Davis, Pharm.D., BCOP | | Clinical Pharmacist Specialist
Atrium Health Levine Cancer
Charlotte, NC | | View Biography |
|
|